Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jun 18;170(12):853-862.
doi: 10.7326/M19-0223. Epub 2019 Jun 11.

Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis

Jordana B Cohen  1 , Michael J Lotito  2 , Usha K Trivedi  3 , Matthew G Denker  1 , Debbie L Cohen  1 , Raymond R Townsend  1
Affiliations
Meta-Analysis

Cardiovascular Events and Mortality in White Coat Hypertension: A Systematic Review and Meta-analysis

Jordana B Cohen et al. Ann Intern Med. .

Abstract

Background: The long-term cardiovascular risk of isolated elevated office blood pressure (BP) is unclear.

Purpose: To summarize the risk for cardiovascular events and all-cause mortality associated with untreated white coat hypertension (WCH) and treated white coat effect (WCE).

Data sources: PubMed and EMBASE, without language restriction, from inception to December 2018.

Study selection: Observational studies with at least 3 years of follow-up evaluating the cardiovascular risk of WCH or WCE compared with normotension.

Data extraction: 2 investigators independently extracted study data and assessed study quality.

Data synthesis: 27 studies were included, comprising 25 786 participants with untreated WCH or treated WCE and 38 487 with normal BP followed for a mean of 3 to 19 years. Compared with normotension, untreated WCH was associated with an increased risk for cardiovascular events (hazard ratio [HR], 1.36 [95% CI, 1.03 to 2.00]), all-cause mortality (HR, 1.33 [CI, 1.07 to 1.67]), and cardiovascular mortality (HR, 2.09 [CI, 1.23 to 4.48]); the risk for WCH was attenuated in studies that included stroke in the definition of cardiovascular events (HR, 1.26 [CI, 1.00 to 1.54]). No significant association was found between treated WCE and cardiovascular events (HR, 1.12 [CI, 0.91 to 1.39]), all-cause mortality (HR, 1.11 [CI, 0.89 to 1.46]), or cardiovascular mortality (HR, 1.04 [CI, 0.65 to 1.66]). The findings persisted across several sensitivity analyses.

Limitation: Paucity of studies evaluating isolated cardiac outcomes or reporting participant race/ethnicity.

Conclusion: Untreated WCH, but not treated WCE, is associated with an increased risk for cardiovascular events and all-cause mortality. Out-of-office BP monitoring is critical in the diagnosis and management of hypertension.

Primary funding source: National Institutes of Health.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Evidence search and selection
Abbreviations: CVD = Cardiovascular disease
Figure 2.
Figure 2.. Cardiovascular event risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
Figure 2.
Figure 2.. Cardiovascular event risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
Figure 2.
Figure 2.. Cardiovascular event risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
Figure 3.
Figure 3.. All-cause mortality risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
Figure 3.
Figure 3.. All-cause mortality risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
Figure 3.
Figure 3.. All-cause mortality risk in white coat hypertension and white coat effect
A) Untreated white coat hypertension B) Treated white coat effect C) Results not stratified by antihypertensive treatment
See this image and copyright information in PMC

Comment in

References

    1. Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1923–94. - PMC - PubMed
    1. Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13–e115. - PubMed
    1. Siu AL, Force USPST. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778–86. - PubMed
    1. Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association. Hypertension. 2019. - PMC - PubMed
    1. Shimbo D, Abdalla M, Falzon L, Townsend RR, Muntner P. Role of Ambulatory and Home Blood Pressure Monitoring in Clinical Practice: A Narrative Review. Ann Intern Med. 2015;163(9):691–700. - PMC - PubMed

Publication types

MeSH terms